drugset
drugset / Trial / NCT05006521

Single and Multiple Ascending Dose Study of KN-002

NCT05006521 ↗

Phase 1 Completed 117 enrolled Kinaset Therapeutics Inc
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a Phase 1, randomized, double-blinded, placebo controlled study. The study consists of 4 parts: Part 1 is a single ascending dose (SAD) study in healthy volunteers; Part 2 is a multiple ascending dose (MAD) study in subjects with stable, mild asthma; Part 3 is a repeat dose in patients with moderate to severe asthma and Part 4 is a repeat dose in patients with COPD.

Timeline

Start
2021-07-30
Primary completion
2023-12-20
Completion
2024-07-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Frevecitinib Small molecule — Inhaled

Indications

No indication recorded.